Skip to main content
. 2021 May 28;59(5):661–665. doi: 10.1016/j.resinv.2021.04.010

Table 1.

Clinical details of patients with COVID-19 pneumomediastinum, divided by epidemic wave.

Pt No. Age, Sex COVID-19 severitya PM Extentb LDH (U/L) Ferritin (ng/mL) D-dimer (ng/mL) Breathings support RRc PEEP (CmH2O) P/F Ratio (mm/Hg) Vt (mL) FiO2 Predisposing factor Predisposing factor location Medications
Wave 1
1 66, M 5 S 603 1289 58000 MV NA 10 220 NA 0.8 Blebs/bullae RUL, LUL None
2 58, M 5 S,P 283 969 1297 MV 22 12 99 550 1.0 Diffuse emphysema All lobes Dex
3 56, M 5 S,P 462 2423 745 MV 28 8 133 600 0.5 None None
4 79, M 4 M 452 340 983 HFNC 21 NA 120 NA N Bullous emphysema RUL (5 cm) Dex
Wave 2
5 19, F 3 S 226 NA 129 Unassisted 19 260 280 NA 0.4 Asthma None
6 60, M 5 L 723 NA 3492 CPAP 18 6 113 NA 1.0 Blebs/bullae RUL, LUL Rem, Dex
7 79, M 5 S 377 3992 5002 MV NA 12 78 NA 0.9 None Dex
8 68, M 4 L 405 666 1597 CPAP 20 8 111 NA 1.0 Traction bronchiectasis ML,RLL, LLL Rem, Dex
9 38, M 5 S 615 NA 2518 CPAP NA 12.5 153 NA 0.6 None NA
10 54, M 5 S 358 1250 1000 CPAP 24 10 132 NA 1.0 None NA
11 78, M 5 S 335 1976 5740 CPAP 18 8 114 560 1.0 Paraseptal emphysema RUL,LUL, RLL Dex
12 65, M 5 S,P 416 1289 997 MV NA 8 110 570 1.0 None NA
13 59, M 4 S 413 3027 1373 Unassisted 22 8 160 NA 0.5 None None
14 90, M 5 S 376 840 1156 CPAP NA 7.5 148 NA 0.1 Bullae/blebs RUL, LUL, LLL, RLL Dex
15 30, F 5 S,P 356 103 13000 CPAPd 20 8 225 400 0.6 None Rem
16 70, M 5 S 380 698 502 MV NA 10 96 550 1.0 ILD, traction bronchiectasis RLL Dex

Legend: CPAP: continuous positive airway pressure (helmet); HFNC: high-flow nasal cannulae; LDH: lactate dehydrogenase; LUL: left upper lobe; LLL: left lower lobe; ML: middle lobe; MV: mechanical ventilation; NA: not available: NTL: neutrophil-to-lymphocyte ratio; PEEP: positive end-expiratory pressure; PM: pneumomediastinum; RLL: right lower lobe; RR: respiratory rate.

All the other reported variables refer to the time when pneumomediastinum occurred. Medications legend: Dex: dexamethasone; Rem: remdesivir (other supportive medications with less specific relation to COVID-19 evolution and pneumomediastinum are not reported).

a

based on computed tomography scan [7], expressed in quintiles.

b

legend for extent of pneumomediastinum: L: light (detected on chest X-ray or at chest palpation), S: severe (obvious swelling extended to chest and neck); M: massive (extending to face and eyelid; required subcutaneous drainage); P: associated pneumothorax.

c

In some patient, respiratory rate refers to the last available record under spontaneous breathing, before orotracheal intubation and mechanical ventilation.

d

in this patient, intubation and mechanical ventilation was initiated very soon after occurrence of pneumomediastinum.